|Day Low/High||21.44 / 22.29|
|52 Wk Low/High||13.67 / 27.80|
Your burning biotech questions answered in our latest mailbag.
We'll answer two of the common questions we have received so far in March.
The South San Francisco, Calif.-based company said Oct. 16 its Phase 3 study of cabozantinib achieved its primary endpoint of overall survival in patients that have advanced hepatocellular carcinoma.
The market is pretty close to where it was during our last update at noon EST. So far it has been a nicely green day across the board. Oncology mid-cap concern Tesaro is not giving up its big takeover speculation rise yesterday and is up another 3%...
Technical indicators indicate the markets are not extended and have consolidated nicely.
Animal health and oncology deal activity is heating up in 2017.
I'm feeling pressure to force some trades today, but I'm trying to stay selective.
I'm underinvested, which isn't good when indices are up.
Interpreting "K-M curves" correctly is an important tool for biotech investors.
The bears are trying it out on the Bank of England news today, but they may get squeezed.
We have a few more days of this slow trading, and it is unlikely to change much.
Only one fund category (of 20) has beaten the S&P 500 over half a decade.
Here is my compilation of last night's profit reports. 24 beats: W&T Offshore (WTI) Oasis Petroleum (OAS) Marathon Oil (MRO) Huntington Ingalls Industries (HII) Cognizant Technology Solutions (CTSH) Disney (DIS) Electronic Arts (EA) Regency Centers ...
Portfolio manager David Peltier discusses how to play one the most volatile low-dollar stocks of 2012.